BioSpace News Archive

Dermata Therapeutics, Inc. announced that Dermata’s CEO, Gerald Proehl, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET.

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 13, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to highlight positive new data on treosulfan that researchers at Toronto’s Princess Margaret Hospital (PMH) recently presented at MDS 2023, the 17th annual International Congress on Myelodysplastic Syndromes, held in Marseille, France.

Catalent, Inc. announced that the Company has received written notification from the New York Stock Exchange that it has officially regained compliance with the NYSE continued listing standards.

McKesson Corporation announced that its previously announced offer to purchase for cash any and all of its outstanding 3.796% Notes due 2024 expired at 5:00 p.m., New York City time, on June 13, 2023.

Personalis, Inc. announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors.

[13-June-2023] VANCOUVER, BC , June 13, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (" BioVaxys " or " Company ") is pleased to announce that it has sold TAET Software Co. to 10402588 BC Ltd (“Purchaser”), a private company formed under the laws of British Columbia , in exchange for 500,000 shares of the Purchaser, with further potential future miles

Inventiva (Euronext Paris and Nasdaq: IVA) today announced positive topline results of the clinical study conducted by Dr. Kenneth Cusi from the University of Florida, evaluating lanifibranor in patients with NAFLD and type 2 diabetes mellitus (T2D).

Gencurix, a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.

Journey Medical Corporation announced positive topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the microbial flora of healthy adults.

Sorrento Therapeutics, Inc. announces it has been awarded a $4.6 million contract from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health for the development of in vitro diagnostics for biodefense, antimicrobial resistant infections and emerging infectious diseases.